摘要
目的探究转移因子口服溶液联合阿奇霉素治疗肺炎支原体肺炎(MPP)患儿的疗效。方法选取我院2017年3月至2019年5月MPP患儿102例,根据治疗方案不同分组,各51例。对照组给予阿奇霉素治疗,观察组于对照组基础上加用转移因子口服溶液。对比两组疗效、症状消失时间、不良反应及治疗前后免疫指标(CD3+、CD4+、CD4+/CD8+)、血清白介素-6(IL-6)、IL-1β、IL-8水平。结果观察组总有效率高于对照组(P<0.05);观察组发热、咳嗽消失时间短于对照组;治疗后观察组CD3+、CD4+、CD4+/CD8+高于对照组;治疗后观察组血清IL-6、IL-1β、IL-8水平低于对照组(P<0.05);两组不良反应无显著差异(P>0.05)。结论转移因子口服溶液联合阿奇霉素治疗MPP患儿,可降低血清IL-6、IL-1β、IL-8水平,改善免疫功能,促进症状改善,疗效显著,安全性高。
Objective To investigate the efficacy of transfer factor oral solution combined with azithromycin in the treatment of mycoplasma pneumoniae pneumonia(MPP).Methods 102 patients with MPP from March 2017 to May 2019 were selected,and 51 cases were divided according to the treatment protocol.The control group was treated with azithromycin,and the observation group was given a transfer factor oral solution on the basis of the control group.The levels of interleukin-6(IL-6),IL-1 and IL-8 were observed in the two groups.Results The total effective rate of the observation group was higher than that of the control group,the time of fever and cough disappearance in the observation group was shorter than that in the control group,the levels of serum IL-6,IL-1βand IL-8 in the observation group were lower than those in the control group after treatment,and there was no significant difference in adverse reactions between the two groups.Conclusion Transfer factor oral solution combined with azithromycin in the treatment of MPP children can reduce the level of serum IL-6,IL-1βand IL-8,promote the improvement of symptoms,the curative effect is significant,and the safety is high.
作者
吴俊平
WU Jun-ping(Department of Pharmacy Zhengzhou Yihe Hospital of Henan Province,Zhengzhou450000 China)
出处
《内蒙古医学杂志》
2020年第10期1167-1169,共3页
Inner Mongolia Medical Journal
基金
郑州市2015年度科技发展计划(编号:20150105)
